IRIS
TIRIBELLI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.590
AS - Asia 4.742
EU - Europa 3.259
SA - Sud America 1.039
AF - Africa 83
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 9
Totale 20.760
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.417
SG - Singapore 2.231
CN - Cina 1.053
UA - Ucraina 882
BR - Brasile 868
HK - Hong Kong 550
DE - Germania 490
VN - Vietnam 394
IT - Italia 344
FI - Finlandia 311
RU - Federazione Russa 289
FR - Francia 216
IE - Irlanda 173
SE - Svezia 172
CA - Canada 121
TR - Turchia 121
GB - Regno Unito 106
IN - India 90
AR - Argentina 84
NL - Olanda 82
KR - Corea 71
PL - Polonia 44
AT - Austria 36
AU - Australia 35
ID - Indonesia 35
BD - Bangladesh 33
IQ - Iraq 31
JP - Giappone 26
ES - Italia 24
MX - Messico 24
IR - Iran 23
EC - Ecuador 22
ZA - Sudafrica 22
MA - Marocco 17
CO - Colombia 15
CZ - Repubblica Ceca 14
GR - Grecia 14
BE - Belgio 13
EG - Egitto 13
PY - Paraguay 13
PK - Pakistan 11
CL - Cile 10
UZ - Uzbekistan 10
PE - Perù 9
AE - Emirati Arabi Uniti 8
TG - Togo 8
VE - Venezuela 8
EU - Europa 7
KE - Kenya 7
SA - Arabia Saudita 7
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
BG - Bulgaria 5
CH - Svizzera 5
CR - Costa Rica 5
JO - Giordania 5
KZ - Kazakistan 5
LT - Lituania 5
OM - Oman 5
ET - Etiopia 4
HU - Ungheria 4
IL - Israele 4
JM - Giamaica 4
KG - Kirghizistan 4
PA - Panama 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BO - Bolivia 3
DK - Danimarca 3
HN - Honduras 3
LU - Lussemburgo 3
LV - Lettonia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
RO - Romania 3
TN - Tunisia 3
AM - Armenia 2
DO - Repubblica Dominicana 2
GA - Gabon 2
HR - Croazia 2
LB - Libano 2
NP - Nepal 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
VC - Saint Vincent e Grenadine 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BF - Burkina Faso 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DM - Dominica 1
GE - Georgia 1
GL - Groenlandia 1
GT - Guatemala 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 20.749
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.487
Fairfield 1.407
Houston 914
Ann Arbor 880
Singapore 847
Ashburn 836
Beijing 588
Seattle 581
Jacksonville 579
Chandler 551
Hong Kong 549
Wilmington 494
Cambridge 474
Dearborn 395
Boardman 240
Princeton 181
Dublin 170
Dallas 145
Los Angeles 136
Ho Chi Minh City 114
Dong Ket 110
Udine 106
Buffalo 101
Izmir 99
Munich 84
San Diego 83
Hefei 77
São Paulo 67
Seoul 65
New York 61
Hanoi 56
Ogden 54
Redondo Beach 53
Amsterdam 47
Des Moines 45
Warsaw 41
Norwalk 37
Nanjing 35
Turku 35
Trieste 34
Ottawa 32
Phoenix 32
Melbourne 28
Tokyo 26
Chevy Chase 25
Nuremberg 25
Santa Clara 24
Rio de Janeiro 23
Calgary 22
Guangzhou 22
Helsinki 22
Mumbai 22
Salvador 22
The Dalles 22
Kunming 21
Belo Horizonte 18
Hangzhou 18
Montreal 18
Porto Alegre 18
Stockholm 18
Vienna 17
London 16
Redmond 16
Chennai 15
Paris 15
Toronto 15
Frankfurt am Main 14
Lille 14
Milan 14
Brussels 13
Denver 13
Duino-Aurisina 13
Vancouver 13
Boston 12
Brasília 11
Caxias do Sul 11
Chicago 11
Istanbul 11
Johannesburg 11
Lappeenranta 11
Orem 11
San Francisco 11
Baton Rouge 10
Bethesda 10
Curitiba 10
Manchester 10
Shanghai 10
St Petersburg 10
Tashkent 10
Atlanta 9
Campinas 9
Corinth 9
Düsseldorf 9
Fonthill 9
Guarulhos 9
Haiphong 9
Jinan 9
Joinville 9
Mexico City 9
New Delhi 9
Totale 13.773
Salva come PNG Salva come JPEG
Nome #
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 435
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 214
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology 202
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 188
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 185
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. 185
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 182
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 176
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 170
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 169
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 167
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 167
Histone post-translational modifications associated to BAALC expression in leukemic cells. 164
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 160
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 157
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 156
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 156
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 155
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 155
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 152
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 152
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 151
All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines 147
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 146
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 143
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 141
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 141
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors 140
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 140
Erratum: Functional regulation of the Apurinic/apyrimidinic endonuclease APE1 by Nucleophosmin (NPM1): Impact on tumor biology 139
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 139
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 139
Unexpected phenotype of a typical NPM1 mutant 138
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 136
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 136
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 135
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 133
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 133
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 133
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. 131
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 131
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 131
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. 131
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. 130
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 129
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia 129
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 129
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia 129
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 128
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. 128
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 128
Evaluation of residual CD34+ Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy 128
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data 127
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 127
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 126
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 126
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 125
ABCB1 (PGP) and ABCG (BCRP) proteins are independent prognostic factors for complete remissione and relapse risk, respectively in normal karyotype adult de novo acute myeloid leukemia. 124
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 124
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 123
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib 123
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 122
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 122
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 122
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. 121
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 120
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicinee—Results from the Italian ‘Back to Life’ project 119
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? 119
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 118
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 118
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia 117
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 117
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients 117
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 117
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 116
How could patient reported outcomes improve patient management in chronic myeloid leukemia? 116
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 116
Prognostic factors anad expression of multidrug-resistance related proteins in 36 patients with acute promyelocytic leukemia. 115
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 115
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 114
The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. 114
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 114
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. 113
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 112
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 111
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase 110
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. 110
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. 109
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 109
A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 420 CASES 108
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 108
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. 108
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience 107
The significance of early warning in chronic myeloid leukemia 107
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 106
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 106
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 105
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 105
GVHD and cyclosporien levels in blood in different moments after allogeneic bone marrow transplantation: an open question? 103
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 103
Totale 13.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.143
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.143
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.480 0 0 0 0 0 298 111 240 306 85 232 208
2021/20221.348 64 145 51 65 23 66 78 60 16 226 325 229
2022/20231.338 199 80 8 156 136 391 6 108 170 24 43 17
2023/2024474 65 48 11 24 52 38 8 49 76 38 24 41
2024/20253.547 79 251 113 141 125 141 235 223 361 331 542 1.005
2025/20264.217 608 773 646 800 1.036 354 0 0 0 0 0 0
Totale 21.249